Brokerages Set Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) PT at $44.25

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $44.25.

A number of equities analysts have weighed in on DMRA shares. Leerink Partners started coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, January 7th. They issued an “outperform” rating and a $46.00 price objective for the company. UBS Group started coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They set a “buy” rating and a $45.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, December 29th. Lifesci Capital raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, February 2nd. Finally, Guggenheim restated a “buy” rating and issued a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th.

Damora Therapeutics, Inc. Common Stock Price Performance

NASDAQ DMRA opened at $25.90 on Friday. The company has a market capitalization of $1.56 billion, a PE ratio of -2.14 and a beta of 1.42. The company has a fifty day moving average of $26.96 and a 200 day moving average of $20.20. Damora Therapeutics, Inc. Common Stock has a 1 year low of $2.01 and a 1 year high of $38.33.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $40,000. Geode Capital Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth approximately $266,000. Virtu Financial LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth approximately $49,000. Sigma Planning Corp acquired a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $334,000. Finally, Two Sigma Investments LP acquired a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $76,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.